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Abstract. Background: Syndromic management of sexually transmissible infections is commonly used in resource-poor
settings for the management of common STIs; abnormal vaginal discharge (AVD) ﬂowcharts are used to identify and treat
cervical infection includingNeisseria gonorrhoea andChlamydia trachomatis. A systematic review and meta-analysis was
undertaken to measure the diagnostic test performance of AVD ﬂowcharts, including both World Health Organization
(WHO)- and locally-adapted AVD ﬂowcharts. Methods: A systematic search of multiple electronic databases was
conducted to locate eligible studies published between 1991 and 2014. Flowcharts were categorised into one of 14 types
based on: 1) use of WHO guidelines or locally-adapted versions; 2) use of risk assessment, clinical examination or both;
and 3) symptomatic entry. Summary diagnostic performance measures calculated included summary sensitivity, summary
speciﬁcity and diagnostic odds ratio. Results: Thirty-six studies, including data on 99 ﬂowcharts, were included in the
review. Summary sensitivity estimates for WHO ﬂowcharts ranged from 41.2 to 43.6%, and for locally adapted ﬂowcharts
from 39.5 to 74.8%. Locally adapted ﬂowcharts performed slightly better than the WHO ﬂowcharts. A difference in
performance was not observed between use of risk assessment or clinical examination. The AVD ﬂowchart performed
slightly better when it was not restricted to symptomatic women only.Conclusions: There was considerable variation in the
performance of the AVD ﬂowchart but overall it was a poor diagnostic tool regardless of whether risk assessment or clinical
examination was included, or whether the ﬂowchart was WHO or locally developed. Many women were treated
unnecessarily and many women with cervical infection were not detected. We caution against their continued use for
management of cervical infection.
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Introduction
Women in resource-poor settings are disproportionately
affected by curable sexually transmissible infections (STIs),
dominated by Neisseria gonorrhoea (NG) and Chlamydia
trachomatis (CT).1,2 Untreated cervical infections can cause
serious complications including infertility, cervical cancer,
spontaneous abortion, premature delivery and low birthweight.3
Syndromic management of STIs is commonly used in settings
where laboratory resources and capacity for etiological diagnoses
are limited in an effort to expedite care and treatment.4–6
Syndromic management of STIs is the presumptive diagnosis
and subsequent treatment of STIs based on the identiﬁcation
of consistent groups of symptoms and easily recognised signs,
with point-of-care therapies used to treat the majority of
organisms responsible for producing speciﬁc syndromes
without a laboratory-conﬁrmed result. The World Health
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Organization (WHO) developed itsﬁrst guidelines for syndromic
management of STIs in 1991;7 ﬂowcharts were developed for
the syndromic detection and treatment of abnormal vaginal
discharge (AVD), urethral discharge, lower abdominal pain and
genital ulcers, among other symptoms.
The AVD ﬂowchart was developed to identify and treat both
cervical (NG and CT) and vaginal infections (Trichomonas
vaginalis, Candida albicans, bacterial vaginosis [BV]). The
ﬁrst WHO guidelines for self-reported AVD, conﬁrmed by
clinical examination and inspection of the cervix, prompted
presumptive treatment for either trichomoniasis and BV or CT
and NG, depending on characteristics of observed discharge.7
Where clinical examination was not possible, patients presenting
with AVD were treated for trichomoniasis and BV as well as CT
and NG if the local prevalence exceeded 10–20%.7 Due to the
asymptomatic nature of cervical CT and NG infections, the
majority of AVD identiﬁed through WHO guidelines were due
to vaginal infection rather than cervical infection8–10 resulting in
over-treatment ofmanywomen for vaginal infections they did not
have, and under-treatment of womenwith asymptomatic cervical
infection. In response, WHO added the use of risk scores to
the ﬂowchart in 1993 to improve its diagnostic performance
and distinguish women with cervical infection from those
with vaginal infection.8,10,11 Several sociodemographic and
behavioural characteristics demonstrated to be associated with
cervical infection were used in the risk score, such as age, marital
status, condom use by the partner, and number of partners.10
WHO also recommended local modiﬁcation of the AVD
ﬂowchart based on local epidemiology.11 In 2003, WHO released
updated guidelines for the management of STIs including updated
ﬂowcharts for AVD incorporating risk assessment.10
Several validation studies have assessed the diagnostic
performance in speciﬁc settings and key populations, however
to our knowledge a systematic review of both WHO and locally-
developed AVD ﬂowcharts has not been conducted to compute
an overall measure of their performance in detecting cervical
infection. A previous systematic review with meta-analysis of
WHO-based AVD ﬂowcharts for cervical and vaginal infections
concluded that the diagnostic performance for identifying
cervical infections was low, and that the AVD ﬂowchart should
focus onmanagement of vaginal infection only.12 Prior literature
reviews have also reported a lower than acceptable performance
of the AVD ﬂowchart.6,13,14 A formal synthesis of data using
both WHO and locally-developed AVD ﬂowcharts is paramount
for the review and possible revision of clinical guidelines. The
objective of this review was to calculate summary estimates of
the diagnostic test performance of AVD ﬂowcharts, including
both WHO and locally-developed ﬂowcharts.
Methodology
Data sources and literature reviews
A systematic search was conducted of electronic databases for
the period 1 January 1991–30 April 2014 to identify all relevant
studies; the start date was chosen based on the release of
the 1991 WHO guidelines. Searches were conducted in April
2009 and repeated in April 2012 and May 2014. Electronic
databases searched included PubMed, OvidMEDLINE, Scopus,
African Medicus Index and LILACs. The search strategy used
combinations of subject-speciﬁc terms relating to STI screening
and testing; for example, the search strategy used for PubMed
database was ‘sexually transmitted diseases/ classiﬁcation’
(MeSH) OR ‘sexually transmitted diseases/diagnosis’ (MeSH)
OR ‘sexually transmitted diseases/epidemiology’ (MeSH) AND
‘ﬂowchart’ OR ‘syndromic*’ AND ‘chlamydia’ OR ‘gonorrhoea’
AND ‘sensitivity’. Non-peer-reviewed literature was also sourced
by searching the bibliographies of eligible studies and broad
Internet searches.
Study selection
One independent reviewer (CvG) performed all aspects of the
search strategy, assessed retrieved abstracts against inclusion
criteria, and reviewed the full text articles in detail. Studies were
included if they: 1) reported measures of diagnostic test accuracy
(including sensitivity and speciﬁcity) where the diagnostic test
was an AVD ﬂowchart and laboratory testing for CT by nucleic
acid ampliﬁcation tests or enzyme immune assay or NGby
culture or enzyme immune assay constituted the gold standard
reference; 2) reported sufﬁcient data to calculate true positives,
false positives, false negatives and true negatives; 3) did not include
HIV-positive women (or data could be identiﬁed for HIV-negative
women); 4) included women aged 16 years and older; 5) were
conducted in resource-poor settings; 6) were published between
1991 and April 2014; and 7) were published in English language.
Women with HIV were excluded as an association between BV
and HIV acquisition has been observed in Africa and AVD is a
symptom of BV.15 In studies where several clinical indicators were
used to detect AVD, only data for clinical identiﬁcation of AVD
were used.
Methodological review
The Quality Assessment for Diagnostic Accuracy Studies
tool (QUADAS)16,17 was used for quality assessment. Each
study was assessed against 11 recommended QUADAS items:
1) representative spectrum; 2) acceptable reference standard; 3)
acceptable delay between tests; 4) partial veriﬁcation avoided;
5) differential veriﬁcation avoided; 6) incorporation avoided
7) reference standard results blinded; 8) index test results
blinded; 9) relevant clinical information; 10) uninterpretable
results reported; 11) withdrawals explained. One additional
QUADAS item was also included in the methodological
assessment: 12) test operators training.17 Data items for
methodological quality were also extracted into Review
Manager 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark)
for descriptive analysis.
Data collection and measurements
Due to the variation in ﬂowcharts used in the studies, ﬂowcharts
were categorised into one of 14 ﬂowchart types. Each study may
have reported the diagnostic test performance for one or more
ﬂowchart types. The ﬁrst level of classiﬁcation was based on
whether ﬂowcharts were WHO-based or locally-adapted. The
second level of classiﬁcation was based on whether they
incorporated clinical examination or risk assessment, or neither
clinical examination or risk assessment. Clinical examination
refers to genital examination by a medical practitioner or nurse,
with or without use of speculum. Risk assessment refers to
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identifying risk factors most closely associated with CT and NG
infection; these include speciﬁc demographic factors (i.e. age),
sexual history, partner’s sexual history and physical signs and
symptoms. A risk score is calculated by summing the number of
afﬁrmative responses to risk assessment questions, and a cut-off
score is used to determine if treatment is indicated or not. Risk
score cut-offs differed in each study. The third level of
classiﬁcation was based on whether patient eligibility to be
assessed by the ﬂowchart included self-reported symptoms
(yes/no, referred to as ‘symptomatic entry’ hereafter. The
ﬂowchart categories were:
* Flowchart 1a:WHO guideline ﬂowchart incorporating clinical
examination only with symptomatic entry
* Flowchart 1b: WHO guideline ﬂowchart incorporating
clinical examination only without symptomatic entry
* Flowchart 2a: WHO guideline ﬂowchart incorporating risk
assessment only with symptomatic entry
* Flowchart 2b: WHO guideline ﬂowchart incorporating risk
assessment only without symptomatic entry
* Flowchart 3a:WHO guideline ﬂowchart incorporating clinical
examination and risk assessment with symptomatic entry
* Flowchart 3b: WHO guideline ﬂowchart incorporating clinical
examination and risk assessment without symptomatic entry
* Flowchart 4a: Locally-adapted ﬂowchart incorporating clinical
examination only with symptomatic entry
* Flowchart 4b: Locally-adapted ﬂowchart incorporating clinical
examination only without symptomatic entry
* Flowchart 5a: Locally-adapted ﬂowchart incorporating risk
assessment only with symptomatic entry
* Flowchart 5b: Locally-adapted ﬂowchart incorporating risk
assessment only without symptomatic entry
* Flowchart 6a: Locally-adapted ﬂowchart incorporating clinical
examination and risk assessment with symptomatic entry
* Flowchart 6b: Locally-adapted ﬂowchart incorporating clinical
examination and risk assessment without symptomatic entry
* Flowchart 7a: Locally-adapted ﬂowchart with no clinical
examination or risk assessment with symptomatic entry
* Flowchart 7b: Locally-adapted ﬂowchart with no clinical
examination or risk assessment without symptomatic entry
Data extraction and management
Data were extracted for each eligible study and entered into
Review Manager 5.3. Where studies evaluated more than
one ﬂowchart, information was extracted and evaluated for each
ﬂowchart. The following data points were extracted for each
ﬂowchart: country of study, year of publication, study setting
(primary health clinic, hospital outpatient department, sexual
health clinic, antenatal clinic, family planning clinic), population
of interest (female sex workers, young females, pregnant
women, other women), self-reported AVD entry to the ﬂowchart
(yes or no), risk assessment score cut-off (number), risk
population (sex workers, pregnant women or young people), use
of speculum in clinical examination (binary), sample size,
prevalence of CT or NG in the study population, ﬂowchart
sensitivity, ﬂowchart speciﬁcity and ﬂowchart positive
predictive value. The number of true positives, false negatives,
true negatives and false positives and associated 95% conﬁdence
intervals were manually calculated using reported data when not
explicitly provided. For each ﬂowchart, the sample prevalence
of cervical infection was calculated as (true positives + false
negatives/true negatives + false positives)100.
Data analysis
Meta-analysis was conducted at the ﬂowchart level; due to
variation between ﬂowcharts used it was not possible to pool
data for different categories such as key population, study setting
or region. Using METANDI and MIDAS, STATA-user-
written programs, pooled meta-analysis of the AVD ﬂowchart
diagnostic accuracy was conducted through application of a
bivariate multilevel random effects modelling approach.18 The
bivariate random-effect model accounts for both the correlation
between study sensitivity and the speciﬁcity estimates, and also
unobserved between-study heterogeneity in test performance
through speciﬁcation of a multilevel bivariate normal regression
approach. The bivariate model estimates pooled sensitivity
and speciﬁcity simultaneously by modelling both diagnostic
parameters as random effects (accounting for between-study
heterogeneity in estimates) with a covariance term to account for
the within-study dependence between these estimates. Summary
diagnostic performancemeasures estimated from themeta-analysis
models included summary sensitivity (SSe), summary speciﬁcity
(SSp), positive and negative likelihood ratios and diagnostic odds
ratio (DOR). Levels of study heterogeneity in pooled analyses
of diagnostic performance (sensitivity and speciﬁcity) were
quantiﬁed using intraclass correlation coefﬁcient (ICC) estimates
for sensitivity and speciﬁcity.19 In order to assess heterogeneity,
subgroup analyses (based on symptomatic entry) were performed;
meta-analyses were conducted for each ﬂowchart (stratiﬁed by
symptomatic entry) in turn. Diagnostic statistics (Cook’s distance
statistics [using a ﬁve parameter model based cut-off]20 and
standardised residual plots) from multi-level bivariate random-
effect models were examined to assess pooled sensitivity and
speciﬁcity estimates for outlier bias.20
STATA version 13 was used in all statistical analyses
(STATA Corporation, College Station, TX, USA). Summary
estimates were estimated when four or more ﬂowcharts could
be included in the analysis, Review Manager 5.3 was used to
generate forest plots to display sensitivity and speciﬁcity
estimates. Open source dot program Graphviz(http://www.
graphviz.org) was used to present the study ﬂow diagram.
Results
Database search results
A total of 393 studies were retrieved from the database searches,
of which 78 were duplicates, resulting in the identiﬁcation of
315 unique studies (Fig. 1). The titles and abstracts of these
studies were then assessed against the inclusion criteria; a total
of 250 studies were excluded on the basis of not being relevant
(n= 172), not meeting the eligibility criteria (n= 75) or full text
not able to be retrieved (n= 3). Sixty-ﬁve studies were then
reviewed in full; additional excluded studies did not provide
sufﬁcient data (n= 5) or did not meet eligibility criteria (n= 24).
A total of 36 met the eligibility criteria and were included.
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Methodological review
The methodological quality of the 36 included studies was high
for the majority of study characteristics with the exception of
test operator training (Fig. 2); approximately one-quarter of
studies had a sufﬁcient level of test operator training. For the
majority of studies the actual level of training achieved was
unclear.
Description of included studies
Study characteristics are presented in Table 1. Half of the included
studies (n=18) were conducted in Africa. Nearly all (n=30) of the
studies were conducted in a healthcare setting; the most common
healthcare settings were primary health clinics (n=10), antenatal
clinics (n=7), and sexual health clinics (n=7). Studies were
published between 1993 and 2009 (median 1996). Study
sample sizes ranged from 116 to 1643 (median 449). Study
prevalence of cervical infection ranged between 0.7% and 35%
(median 12%). We note that summary estimates could not be
calculated using broad descriptors used here due to variation in
ﬂowcharts used.
Assessment of heterogeneity
Of the 14 potential ﬂowchart types there were four that had four
or fewer studies describe that ﬂowchart; hence Cook’s distance
statistics could not be calculated. Cook’s distance statistics
could be calculated for studies using the 10 other ﬂowchart
types; three ﬂowchart types had Cook’s distance statistics
greater than the established cut-off value indicating outliers
within the ﬂowchart grouping and these outlier studies were
excluded from the calculation of summary statistics, one study
was excluded from Flowchart 4a, two studies were excluded
from Flowchart 5b and two studies were excluded from
Flowchart 6b (Fig. 3). There was considerable heterogeneity
between studies for all ﬂowcharts included in meta-analyses,
with an intraclass correlation coefﬁcient range of 0.01–0.54 for
sensitivity and 0.03–0.45 for speciﬁcity (Table 2).
Description of ﬂowcharts and summary estimates
Key study parameters of individual ﬂowchart types including
ﬂowchart sensitivity and speciﬁcity are presented in Fig. 4.
Table 2 describes included ﬂowcharts and summary estimates
calculated for each ﬂowchart type. Ninety-nine individual
ﬂowcharts were identiﬁed from the 36 studies; the majority
(n= 59, 70%) of included ﬂowcharts were locally-adapted.
Among WHO ﬂowcharts, the greatest number of included
Ovid Scopus
1/1/1991–31/12/2004 1/1/1991–31/12/2004
68 citations 28 citations
Medline
1/1/1991–31/12/2004
112 citations
LILACs
1/1/1991–31/12/2004
18 citations
African Index Medicus Database
1/1/1991–31/12/2004
167 citations
315 non–duplicate citations screened
inclusion/exclusion criteria applied
65 articles retrieved
inclusion/exclusion
criteria applied
36 articles included
24 articles excluded after full text screen 5 articles excluded during data extraction
250 articles excluded after title/abstract screen
Fig. 1. Study ﬂow diagram.
Representative spectrurn?
Acceptable reference standard?
Acceptable delay between tests?
Partial verification avoided?
Differential verification avoided?
Incorporation avoided?
Index test results blinded?
Relevant clinical information?
Uninterpretable results reported?
Withdrawals explained?
Test operator training
0% 25% 50% 75% 100%
Reference standard results blinded?
Yes (high quality) Unclear No (low quality) 
Fig. 2. Methodological quality of included studies using the Quality
Assessment for Diagnostic Accuracy Studies tool.
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studies used risk assessment only (n= 14). Among locally-
developed ﬂowcharts, the greatest number of included studies
also used risk assessment only (n= 20). SSe among WHO
ﬂowcharts ranged from 41.2% (Flowchart 3a) to 43.6%
(Flowchart 2a). SSp among WHO-developed ﬂowcharts ranged
from 68.7% (Flowchart 3a) to 76.2% (Flowchart 2a). Summary
estimates for DOR among WHO-developed ﬂowcharts ranged
from 1.5% (Flowchart 3a) to 2.5% (Flowchart 2a). SSe among
locally-adapted ﬂowcharts ranged from 39.5% (Flowchart 4a)
to 74.8% (Flowchart 6b). SSp among locally-adapted ﬂowcharts
ranged from 53.6% (Flowchart 6b) to 75.6% (Flowchart 5a
and 6a). Summary estimates for DOR among locally-adapted
ﬂowcharts ranged from 1.2% (Flowchart 7a) to 3.4 (Flowchart
5b). Overall, the ﬂowchart with the greatest DOR (a ratio of
the odds of a test being positive if the subject was a true case
relative to the odds of a test being positive if the subject was
Table 1. Characteristics of included studies
ANC, antenatal clinic; CS, community setting; CT, Chlamydia trachomatis; FPC, family planning clinic; FSW, female sex workers; HOP, hospital outpatient
clinic; NG, Neisseria gonorrhoea; NGO, nongovernment organisation health clinic; PHC, primary health clinic; SHC, sexual health clinic; SO, street outreach
Author, year WHO region Study population Setting Cervical
infections
included
Total
sample
size
Flowchart
types
evaluatedA
Number of
ﬂowcharts
evaluated
Vuylsteke, 19931 African region Pregnant women, FSW ANC, PHC CT and NG 1160, 1222B 1a, 3b, 7a 5
Mayaud, 199521 African region Pregnant women ANC CT and NG 964 2a, 4a, 5b, 6b, 7a 6
Ronsmans, 199622 European region Women CS CT only 867 2a, 3a, 5a, 7b 4
Meda, 199723 African region Pregnant women ANC CT and NG 645 6b 1
Alary, 199824 African region Women PHC CT and NG 481 2a,3a 2
Behets, 199825 Region of the Americas Women FPC CT and NG 767 4b 1
Bourgeois, 1998a26 African region Pregnant women ANC CT and NG 646 6b 2
Bourgeois 1998b27 African region Pregnant women ANC CT and NG 646 6b 1
Costello Daly, 199828 African region Women HOP CT and NG 550 2a, 3a, 5a, 6a 4
Mayaud, 199829 African region Pregnant women ANC CT and NG 660 2a, 4a, 6a 3
Mayaud, 199830 African region Pregnant women ANC CT and NG 395, 628B 1a, 2a 2
Moherdaui, 199831 Region of the Americas Women SHC CT and NG 348 5a, 6a 2
Ndoye 199832 African region FSW SHC CT and NG 374 4b, 5b 2
O’Diallo, 199833 African region FSW SHC CT and NG 683 1a, 2a, 4b, 5b, 6b 5
Passey, 199834 Western Paciﬁc region Women CS CT and NG 192, 200B 3a, 5b, 6a 10
Ryan, 199835 Eastern Mediterranean Women PHC, FPC CT and NG 1238 2a, 3a 4
Schneider, 199836 African region Women FPC CT and NG 249 6b 1
Wi, 199837 Western Paciﬁc Region FSW SO, PHCs CT and NG 245 4b, 5b 2
Hawkes, 199938 South-East Asia region Women PHC CT and NG 449 2a, 4a 2
Fonck, 200039 African region Women PHC, SHC CT and NG 621 2a, 4a, 5a, 6a, 7a, 7b 12
Iskandar, 200040 South-East Asia region Women FPC CT and NG 486 4b, 5b, 7b 3
Vishwanath, 200041 South-East Asia region Women FPC CT and NG 320 6a 1
Ward, 200142 Region of the Americas Women FPC CT and NG 182 6b 1
Mukenge-Tshibaka, 200243 African region FSW STD CT and NG 481 4b 1
Desai, 200344 South-East Asia region FSW STD CT and NG 118 6b 1
Kaufman, 200344 Western Paciﬁc region Women CS CT only 1643 4a, 7b 2
Vuylsteke, 200345 African region FSW SHC CT and NG 118 6a 1
García, 200446) Region of the Americas Women NGO CT and NG 754 5b 1
Pépin, 200447 African region Women PHC CT and NG 726 4a 2
Råssjö, 200648 African region Adolescents PHC CT and NG 199 1b, 3a, 5b, 7b 7
Smith Fawzi, 200649 Region of the Americas Women PHC CT and NG 3956 5a 2
Romoren, 200750) African region Pregnant women ANC CT and NG 703 4b, 5b, 6b 3
Zribi, 200851 Eastern Mediterranean Women PHC CT and NG 116 3b 1
Clark, 200952 Region of the Americas Women CS CT and NG 320 5b 1
Guimaraes, 200953 Region of the Americas Adolescents PHC CT and NG 914 2b 1
AFlowchart type descriptions: 1a: WHO guideline ﬂowchart incorporating clinical examination only with symptomatic entry; 1b: WHO guideline ﬂowchart
incorporating clinical examination only without symptomatic entry; 2a: WHO guideline ﬂowchart incorporating risk assessment only with symptomatic
entry; 2b: WHO guideline ﬂowchart incorporating risk assessment only without symptomatic entry; 3a: WHO guideline ﬂowchart incorporating clinical
examination and risk assessment with symptomatic entry; 3b: WHO WHO guideline ﬂowchart incorporating clinical examination and risk assessment
without symptomatic entry; 4a: Locally-adapted ﬂowchart incorporating clinical examination only with symptomatic entry; 4b: Locally-adapted ﬂowchart
incorporating clinical examination only without symptomatic entry; 5a: Locally-adapted ﬂowchart incorporating risk assessment only with symptomatic
entry; 5b: Locally-adapted ﬂowchart incorporating risk assessment only without symptomatic entry; 6a: Locally-adapted ﬂowchart incorporating clinical
examination and risk assessment with symptomatic entry; 6b: Locally-adapted ﬂowchart incorporating clinical examination and risk assessment without
symptomatic entry; 7a: Locally-adapted ﬂowchart with no clinical examination or risk assessment with symptomatic entry; 7b: Locally-adapted ﬂowchart
with no clinical examination or risk assessment without symptomatic entry.
BTwo sample sizes are included due to study presenting data for more than one study population.
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not a true case) was 6b (locally-adapted ﬂowchart incorporating
clinical examination and risk assessment without symptomatic
entry).
Comparison of WHO and locally-adapted ﬂowcharts
Due to the limited number of similar WHO and locally-adapted
ﬂowcharts, comparisons for WHO-based and locally-adapted
ﬂowcharts could only be made between Flowchart 2a and
Flowchart 5a (both using risk assessment only with symptomatic
entry), and between Flowchart 3a and Flowchart 6a (both using
clinical examination and risk assessment with symptomatic
entry). For both comparisons, the locally-adapted ﬂowcharts
performed slightly better than theWHOequivalent. For example,
Flowchart 5a (locally-adapted ﬂowchart incorporating risk
assessment only with symptomatic entry) had a higher DOR
than Flowchart 2a (WHO guideline ﬂowchart incorporating risk
assessmentonlywithsymptomaticentry,DOR= 3.3v.DOR=2.5).
Flowchart 6a (locally-adapted ﬂowchart incorporating clinical
examination and risk assessment with symptomatic entry)
had similar pooled sensitivity and speciﬁcity to Flowchart 3a
(WHO guideline ﬂowchart incorporating clinical examination
and risk assessment with symptomatic entry), however the
DOR was higher for Flowchart 6a (DOR= 2.4) compared with
Flowchart3a(DOR= 1.5).
Comparison of ﬂowcharts using risk assessment, clinical
examination or both
A difference was not observed between the performance of
ﬂowcharts that included clinical assessment or risk assessment;
however the ﬂowchart that incorporated neither (Flowchart 7a)
had the lowest DOR of all ﬂowcharts included in this study.
Flowchart 7a also had low SSe (47.8%) and moderate SSp
(64.0%).
Comparison of symptomatic entry
Pooled diagnostic performance estimates suggest improved
performance when the AVD ﬂowchart was not restricted to
participants with self-reported AVD symptoms (Table 2).
Pooled estimates of ﬂowcharts dependent on self-reported
symptoms by study participants could be calculated for
Flowcharts 4–6 (all locally-adapted); the pooled sensitivity
estimate was higher when ﬂowcharts were not restricted to
those participants with self-reported AVD symptoms. For
example, the SSe for Flowchart 4a and 4b were 39.5% and
63.6%), respectively. The speciﬁcity, however, was higher when
ﬂowcharts were validated by participants self-reporting AVD
symptoms; for example, the SSp for Flowchart 5a and 5b were
75.6% and 61.9%, respectively.
Cooks distance threshold = 1.7
Co
ok
s 
Di
st
an
ce
2
1.
5
1
.
5
0
0 20 40 60 80
Cooks distance threshold = 2.5
Co
ok
s 
Di
st
an
ce
2
1.
5
1
.
5
0
0 20 40 60 80 100
Cooks distance threshold = 2.0
Co
ok
s 
Di
st
an
ce
2
1.
5
1
.
5
0
0 20 40 60 80 100
Flowchart 2 (symptomatic)
Flowchart 4 (symptomatic)
Flowchart 6 (symptomatic)
Cooks distance threshold = 1.5
Co
ok
s 
Di
st
an
ce
5
3
4
2
1
0
0 20 40 60 80 100
Flowchart 6 (symptomatic)
Cooks distance threshold = 5.0
Co
ok
s 
Di
st
an
ce
5
3
4
2
1
0
20 40 60 80 100
Flowchart 6 (symptomatic)
Cooks distance threshold = 4.0
Co
ok
s 
Di
st
an
ce
2
3
4
5
1
0
0 20 40 60 80 100
Flowchart 5 (symptomatic)
Cooks distance threshold = 1.3
Co
ok
s 
Di
st
an
ce
1
1.
5
2
.
5
0
0 20 40 60 80 100
Flowchart 5 (symptomatic)
Cooks distance threshold = 1.8
Co
ok
s 
Di
st
an
ce
2
1.
5
1
.
5
0
0 20 40 60 80 100
Flowchart 3 (symptomatic)
Cooks distance threshold = 2.5
Co
ok
s 
Di
st
an
ce
5
3
4
2
1
0
0 20 40 60 80
Flowchart 4 (symptomatic)
Fig. 3. Calculated Cook’s distance statistics, by ﬂowchart.
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Discussion
The present study provides a much-needed summary of the
evidence on the performance of WHO and locally-adapted
AVD ﬂowcharts to detect cervical infection. Although some
ﬂowcharts performed better than others, summary diagnostic
performance estimates were consistently low for all ﬂowcharts,
regardless of whether ﬂowcharts incorporated risk assessment
or clinical examination, if they were WHO-based or locally-
adapted, or if they were only applied to women self-reporting
AVD symptoms. These ﬁndings call for a revision of the
inclusion of the AVD ﬂowchart in WHO and local guidelines
for STI management.
The results suggest the inclusion of risk assessment or
clinical examination in locally-adapted ﬂowcharts improves the
ability of ﬂowcharts to correctly identify women with cervical
infection (sensitivity) and correctly identify women as not having
cervical infection (speciﬁcity). The improvement in sensitivity was
greatest if the ﬂowchart was used at a population level rather
than selectively among women self-reporting AVD symptoms.
However, the improvement was marginal and the level of
sensitivity and speciﬁcity remained low.
Overall, AVD ﬂowcharts performed better in terms of SSe
and DOR when they were not dependent on women self-
reporting symptoms of AVD. Although DOR was higher among
ﬂowcharts which were not dependent on women self-reporting
AVD symptoms, the corresponding SSe remained low, with only
60–75% of women with cervical infection being detected
through the ﬂowchart. As a result, up to 40% of women with
likely cervical infection would remain untreated using these
ﬂowcharts. With any screening or diagnostic test, it is important
to weigh up the consequences of leaving cases undetected and
untreated against incorrect classiﬁcation and treatment of false
positive cases. False positive cases can lead to unnecessary
expense for the healthcare system on drug expenditure, potential
side effects for participants and unnecessary notiﬁcation of
sexual partners, which in some settings puts women at risk. A
high speciﬁcity is important to reduce unnecessary treatment
whereas a high sensitivity will reduce false negative cases and
ensure people with infection receive appropriate treatment and
follow-up, including partner notiﬁcation and STI counselling.
The serious public health consequences of undiagnosed and
untreated cervical infection in the community suggest that
trading speciﬁcity for higher sensitivity is arguably warranted.
In situations where both sensitivity and speciﬁcity are
unacceptably low a screening tool should not be used as they
provide a false impression about the ability to accurately
diagnose infection. With this in mind, the results of this review
support the removal of the AVD ﬂowchart for the syndromic
management of STIs and in national STI control policies in
resource-poor settings globally. In settings of high prevalence of
chlamydia where laboratory diagnosis is not possible, it may be
warranted to implement a mass treatment program rather than
screening.54 It is important to note, however, that laboratory
diagnosis of STIs is the gold standard and where possible should
Table 2. Summary estimates of the diagnostic test performance of AVD ﬂowcharts
CI , conﬁdence interval; DOR, diagnostic odds ratio; LR, likelihood ratio; NC, not calculated; NS, no symptomatic entry; S, symptomatic entry; SSe, summary
sensitivity; SSp, summary speciﬁcity; ICC, intraclass correlation coefﬁcient; Se, sensitivity; Sp, speciﬁcity; CE, clinical examination; RA, risk assessment
Flowchart typesA Studies
(n)
Number
included in
calculation of
summary
estimate (n)
SSe
(95% CI)
ICC Se SSp
(95% CI)
ICC Sp LR+
(95% CI)
LR
(95% CI)
DOR
(95% CI)
WHO ﬂowcharts 30
Flowchart 1: CE only 3
Flowchart 1a: CE-only (S) 2 0 NC NC NC NC NC NC NC
Flowchart 1b: CE-only (NS) 1 0 NC NC NC NC NC NC NC
Flowchart 2: RA only 14
Flowchart 2a: RA only (S) 12 12 43.6 (31.0–57.1) 0.20 76.2 (65.2–84.6) 0.21 1.8 (1.6–2.1) 0.7 (0.7–0.8) 2.5 (2.1–3.0)
Flowchart 2b: RA only (NS) 2 0 NC NC NC NC NC NC NC
Flowchart 3: CE and RA 13
Flowchart 3a: CE and RA (S) 11 11 41.2 (24.8–59.9) 0.31 68.7 (52.4–81.4) 0.29 1.3 (1.1–2.1) 0.8 (0.7–1.0) 1.5 (1.1–2.1)
Flowchart 3b: CE and RA (NS) 2 0 NC NC NC NC NC
Locally-adapted ﬂowcharts 59
Flowchart 4: CE only 16
Flowchart 4a: CE only (S) 8 7 39.5 (31.5–48.0) 0.03 70.6 (65.4–75.4) 0.03 1.3 (1.1–1.7) 0.9 (0.8–1.0) 1.6 (1.1–2.2)
Flowchart 4b: CE only (NS) 8 8 63.6 (47.6–77.0) 0.20 62.3 (44.4–77.4) 0.25 1.7 (1.9. 4.5) 0.6 (0.5. 0.7) 3.0 (2.0.–4.0)
Flowchart 5: RA only 20
Flowchart 5a: RA only (S) 5 5 51.2 (15.7–85.6) 0.54 75.6 (42.7–92.8) 0.45 2.1 (1.6–2.8) 0.6 (0.4–1.1) 3.3 (2.2–4.9)
Flowchart 5b: RA only (NS) 15 13 60.3 (47.2–72.0) 0.20 61.9 (50.5–72.1) 0.18 1.6 (1.4–1.8) 0.6 (0.5–0.8) 2.5 (1.9–3.2)
Flowchart 6: CE and RA 23
Flowchart 6a: CE and RA (S) 10 10 43.3 (25.9–62.6) 0.31 75.6 (61.2–85.9) 0.26 1.8 (1.5–2.1) 0.7 (0.6–0.9) 2.4 (1.9–3.0)
Flowchart 6b: CE and RA (NS) 13 11 74.8 (67.0–81.2) 0.09 53.6 (46.2–60.8) 0.07 1.6 (1.5–1.8) 0.5 (0.4–0.6) 3.4 (2.8–4.2)
Flowchart 7: No RA or CE 10
Flowchart 7a: No RA or CE (S) 5 5 47.8 (41.7–53.9) 0.01 64 (56.2–71.0) 0.04 1.3 (1.1–1.6) 0.8 (0.7–0.9) 1.2 (1.0–1.4)
Flowchart 7b: No RA or CE (NS) 5 5 38.9 (23.7–56.5) 0.15 66.4 (48.7–80.4) 0.17 1.16 (1.0–1.4) 0.9 (0.8–1.0) 1.3 (0.9–1.7)
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Flowchart 1 (WHO flowchart - clinical examination only)
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Fig. 4. Forest plot of the sensitivity and speciﬁcity of abnormal vaginal discharge ﬂowcharts.
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Fig. 4. (Continued)
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be used rather than presumptive treatment. For example, new
molecular-based point-of-care tests for the simultaneous
detection of CT and NG in community-health settings in remote
Australia have been evaluated to have high sensitivity and
speciﬁcity and operational beneﬁts in terms of resources and
ease of use55 and may offer a more suitable alternative to
syndromic management in resource-poor settings globally.
Several limitations should be considered in the interpretation
of the present study. First there was considerable heterogeneity
across studies and within ﬂowchart categories. Included studies
represented populations that were diverse in geography, risk
proﬁle and setting. Although efforts were made to compare
homogenous studies in terms of ﬂowchart description and
dependence on self-reported symptoms, it was not feasible to
further stratify due to the limited number of ﬂowcharts identiﬁed.
Additional analysis explored differences in ﬂowchart performance
by cervical infection prevalence (low, medium and high) and risk
proﬁle (sex workers, pregnant women) but did not ﬁnd a difference
and these results are not reported here. Second, ﬂowcharts were
not consistently described and reported and it is possible that
ﬂowcharts weremisclassiﬁed; the effect ofmisclassiﬁcation cannot
be estimated. Similarly, ﬂowchart test performance measures were
also not consistently reported leading to potential errors in the
derived number of true positives and false positives. It was also not
possible to estimate the effect of this potential bias. Only English
language publications were included in this review, and one
reviewer retrieved the studies and extracted data.
Conclusion
Various iterations of AVD ﬂowcharts are currently used in STI
guidelines in resource-poor settings globally, including WHO and
locally- adapted versions, due to their low cost and lack of reliance
on laboratory diagnostics. Our systematic review of the diagnostic
performance of the AVD ﬂowchart provides further evidence that
the performance of the AVD is both inadequate and lacking in
evidence. Many women were treated unnecessarily and many
women with cervical infection were not detected and therefore
not treated. We therefore caution against the continued use of
these ﬂowcharts as they create a false impression of being able to
identify and improve the management of women infected with
chlamydia and gonorrhoea. We recommend that in future the
WHO Guidelines for the Management of Sexually Transmitted
Infections10 exclude syndromic management of AVD to detect
cervical infection.
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